186 related articles for article (PubMed ID: 29498535)
1. Patient perspectives on repeated MRI and PET/CT examinations during neoadjuvant treatment of esophageal cancer.
Goense L; Borggreve AS; Heethuis SE; van Lier AL; van Hillegersberg R; Mook S; Meijer GJ; van Rossum PSN; Ruurda JP
Br J Radiol; 2018 Jun; 91(1086):20170710. PubMed ID: 29498535
[TBL] [Abstract][Full Text] [Related]
2. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
[TBL] [Abstract][Full Text] [Related]
3. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
[TBL] [Abstract][Full Text] [Related]
4. 18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapy.
Valkema MJ; de Lussanet de la Sablonière QG; Valkema R; Thomeer MGJ; Dwarkasing RS; Harteveld AA; Doukas M; Mostert B; van der Zijden CJ; van der Sluis PC; Lagarde SM; Wijnhoven BPL; Verburg FA; van Lanschot JJB
Nucl Med Commun; 2024 Feb; 45(2):128-138. PubMed ID: 37982560
[TBL] [Abstract][Full Text] [Related]
5. Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?
Heneghan HM; Donohoe C; Elliot J; Ahmed Z; Malik V; Ravi N; Reynolds JV
Ann Surg; 2016 Nov; 264(5):831-838. PubMed ID: 27741010
[TBL] [Abstract][Full Text] [Related]
6. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
Vollenbrock SE; Voncken FEM; Lambregts DMJ; Maas M; Donswijk ML; Vegt E; Ter Beek LC; van Dieren JM; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):176-185. PubMed ID: 32572560
[TBL] [Abstract][Full Text] [Related]
7. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the psychological burden of PET/MRI and PET/CT scans and association to initial state anxiety and previous imaging experiences.
Shortman RI; Neriman D; Hoath J; Millner L; Endozo R; Azzopardi G; O'Meara C; Bomanji J; Groves AM
Br J Radiol; 2015 Aug; 88(1052):20150121. PubMed ID: 26090825
[TBL] [Abstract][Full Text] [Related]
9. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of Clinically Complete Responders Using Serial
Valkema MJ; van der Wilk BJ; Eyck BM; Wijnhoven BPL; Spaander MCW; Doukas M; Lagarde SM; Schreurs WMJ; Roef MJ; van Lanschot JJB; Valkema R
J Nucl Med; 2021 Apr; 62(4):486-492. PubMed ID: 32887759
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making.
Anderegg MC; de Groof EJ; Gisbertz SS; Bennink RJ; Lagarde SM; Klinkenbijl JH; Dijkgraaf MG; Bergman JJ; Hulshof MC; van Laarhoven HW; van Berge Henegouwen MI
PLoS One; 2015; 10(11):e0133690. PubMed ID: 26529313
[TBL] [Abstract][Full Text] [Related]
12. Role of
Sasaki K; Uchikado Y; Okumura H; Omoto I; Kita Y; Arigami T; Uenosono Y; Owaki T; Maemura K; Natsugoe S
Anticancer Res; 2017 Feb; 37(2):859-864. PubMed ID: 28179343
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Computerized Tomography (PET-CT) Scan in Identifying Interval Metastases for Patients with Esophageal Cancer.
Gabriel E; Alnaji R; Du W; Attwood K; Kukar M; Hochwald S
Ann Surg Oncol; 2017 Jun; 24(6):1739-1746. PubMed ID: 28058562
[TBL] [Abstract][Full Text] [Related]
15. Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.
Voncken FEM; Aleman BMP; van Dieren JM; Grootscholten C; Lalezari F; van Sandick JW; Steinberg JD; Vegt E
Strahlenther Onkol; 2018 Feb; 194(2):156-163. PubMed ID: 29051991
[TBL] [Abstract][Full Text] [Related]
16. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
[TBL] [Abstract][Full Text] [Related]
17. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
[TBL] [Abstract][Full Text] [Related]
18. Perceived patient burden and acceptability of whole body MRI for staging lung and colorectal cancer; comparison with standard staging investigations.
Evans RE; Taylor SA; Beare S; Halligan S; Morton A; Oliver A; Rockall A; Miles A
Br J Radiol; 2018 Jun; 91(1086):20170731. PubMed ID: 29528257
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging
Beukinga RJ; Hulshoff JB; Mul VEM; Noordzij W; Kats-Ugurlu G; Slart RHJA; Plukker JTM
Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
